Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Anna K Nowak, W Joost Lesterhuis, Peey-Sei Kok, Chris Brown, Brett Gm Hughes, Deme J Karikios, Thomas John, Steven C-H Kao, Connull Leslie, Alistair M Cook, Nick Pavlakis, Karen Briscoe, Kenneth J O'Byrne, Christos S Karapetis, Wei-Sen Lam, Ailsa Langford, Sonia Yip, Martin R Stockler
The Lancet Oncology | Published : 2020
BACKGROUND: There is a strong unmet need to improve systemic therapy in mesothelioma. Chemotherapy with cisplatin and pemetrexed improves survival in malignant pleural mesothelioma, and immune checkpoint inhibitors are an emerging treatment in this disease. We aimed to evaluate the activity of durvalumab, an anti-PD-L1 antibody, given during and after first-line chemotherapy with cisplatin and pemetrexed in patients with advanced malignant pleural mesothelioma. METHODS: DREAM was a multicentre, single-arm, open-label, phase 2 trial done in nine hospitals in Australia. Eligible patients were aged 18 years or older and had histologically confirmed malignant pleural mesothelioma considered unsu..View full abstract